Loading data for SOBI.ST — first visit, this takes a few seconds.
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Stockholm: SOBI.ST
· Real-Time Price · USD
458.40
+8.60 (1.91%)
At close: Sep 04, 2026, 3:29 PM
The price, the headline numbers and the latest news, in one place.
Swedish Orphan Biovitrum AB (publ) (SOBI.ST) Stock Price, Analysis & Data
No data available
| Bid | 457.4 |
| Market Cap | 159B |
| Revenue (ttm) | 30.6B |
| Net Income (ttm) | 1.38B |
| 0.28 | |
| 3.91 | |
| 116.32 | |
| 29.25 | |
| P/B (ttm) | 3.74 |
| P/S (ttm) | 5.18 |
| Earnings Date | n/a |
| Ask | 458.8 |
| Volume | 52,851 |
| Avg. Volume (20D) | 400,314 |
| Open | 450.00 |
| Previous Close | 449.80 |
| Day's Range | 450.00 - 458.40 |
| 52-Week Range | 262.80 - 487.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SOBI.ST
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adul...
Sector Healthcare
IPO Date Sep 15, 2006
Employees 2,119
Stock Exchange Stockholm
Ticker Symbol SOBI.ST
Website https://www.sobi.com
Financial Performance
In 2025, Swedish Orphan Biovitrum AB (publ)'s revenue was 28.24B, an increase of 8.5% compared to the previous year's 26.03B. Earnings were 478M, a decrease of -87.7%.
Financial numbers in SEK Financial StatementsEarnings Surprise
Swedish Orphan Biovitrum AB (publ) has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.